Shanghai Aohua Photoelectricity Endoscope Co. Ltd. A (688212) fair value: what the stock is really worth
As of Oct 27, 2026: fair value (intrinsic value) of Shanghai Aohua Photoelectricity Endoscope Co. Ltd. A stock ¥10.08, price ¥27.58, upside -63.5%, quality 43 out of 100. Rating: strongly overvalued. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Fair value above price?No
Good quality?No
Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with oneYes, for free
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Oct 26, 2026.
How to read this chart
59‑month range ¥24.71 – ¥81.58 · fair‑value band ¥9.27 – ¥10.08 · the ¥27.58 price screens above the ¥10.08 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Oct 26, 2026.
Follow Shanghai Aohua Photoelectricity Endoscope Co. Ltd. A in your weekly email
Every Wednesday you see whether Shanghai Aohua Photoelectricity Endoscope Co. Ltd. A is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Shanghai Aohua Photoelectricity Endoscope Co., Ltd. engages in the research and development, manufacture, and sale of electronic endoscope equipment and endoscopic diagnosis and treatment consumables in China and internationally.
Show moreShow less
It offers electronic digestive endoscopes, otolaryngoscopes, bronchoscopes, and endoscopic diagnostic and treatment consumables for use in respiratory medicine, general surgery, otolaryngology, orthopedics, urology, gynecology, gastroenterology, and emergency medicine.
Shanghai Aohua Photoelectricity Endoscope Co., Ltd. was founded in 1994 and is based in Shanghai, China.
Stock analysis
Shanghai Aohua Photoelectricity Endoscope Co. Ltd. A (688212) currently trades at ¥27.58, while our model-based Fair Value estimate is ¥10.08, 63.5% below the price, so the stock looks overvalued today.
Show more
Valuation
Bull case: the Multiples group reads highest at a median of ¥6.37 per share, and 1 of the 16 models we run sit above the ¥27.58 price.
Bear case: the Earnings-Based group reads lowest at ¥1.39, and 15 of the 16 models stay below the price. Data coverage for this calculation is low.
Scenario range: ¥9.27 (bear) to ¥10.08 (bull), the price of ¥27.58 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 43/100 (below-average quality), in the Healthcare sector.
Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Shanghai Aohua Photoelectricity Endoscope Co. Ltd. A reported revenue of 774M CNY in FY2025 versus 347M CNY in FY2021, a compound +22.2%/yr. Reported net income was 11.5M CNY in FY2025, compounding −33.1%/yr from FY2021.
Key figures
Market cap 3.7B CNY (≈ $558M) Small · P/E ratio 235.0 · P/S ratio 3.48 · EPS (TTM) ¥−0.2500 · Dividend yield 0.4% · Net margin −4.2% · Return on equity −2.6% · Return on assets (EBIT) 2.7%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 14 out of 100 (low confidence).
What moves the price
The share trades about 46% below its 52-week high and 12% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −3% fair-value upside, at −63%, 688212 screens richer than that median.
Fair Value models
The price assumes far more growth than our models allow for, so the models scatter widely (¥1.39 to ¥39.94). Read the Fair Value as a cautious anchor, not a price target; the Growth Forecast section shows what the price assumes.
Bear¥9.27Fair Value ¥10.08Bull¥10.08
Price ¥27.58 · Upside -63.5%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
Residual Income¥6.12¥5.61¥5.2676
ROIC Compounder¥4.15¥4.39¥4.5872
EPV¥4.15¥4.39¥4.5871
All 16 models by family
Earnings-Based
Graham-Dodd¥0.5800¥3.42¥4.7663
Lynch FV¥0.9700¥1.39¥1.8061
PEG = 1.0¥0.9700¥1.39¥1.8057
EPV¥4.15¥4.39¥4.5871
Dividend Discount
Gordon GGM¥0.8900¥1.54¥2.0468
DDM Multi-Stage¥0.8900¥1.44¥1.6567
Multiples
P/E Multiple¥1.40¥1.87¥2.3463
P/S Multiple¥1.08¥1.45¥1.8158
P/B Multiple¥29.95¥39.94¥49.9255
EV/EBIT¥6.30¥7.62¥8.9566
EV/EBITDA¥11.30¥14.30¥17.2967
EV/Revenue¥5.16¥6.37¥7.5954
Asset-Based
NCAV (Graham)¥2.01¥3.05¥3.8154
Economic Profit
Residual Income¥6.12¥5.61¥5.2676
ROIC Compounder¥4.15¥4.39¥4.5872
Growth Earnings
Growth-Adj P/E¥1.45¥2.07¥2.7067
The fair value above starts from this blend and is adjusted for a year distorted by one-off effects.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.58/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+3.2%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+20.2%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+24.1%
Start year 2020 (pandemic)
Revenue growth 6 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+17.3%
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Basis: EBIT basis.
−8.3%
Earnings growth per share plus dividend.
Earnings per share, growth per year−8.7%
Dividend (yield on the price)0.4%
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.11% → 5%
Compare Shanghai Aohua Photoelectricity Endoscope Co. Ltd. A with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Devices · 324 stocks
Beats the industry median on 1/11 measures
Overall it trails its industry peers.
Valuation
Quality Score43 · Below median
Fair Value upside−63.5% · Bottom 25%
Profitability
Return on assets0.6% · Below median
Net margin (12 months)−4.2% · Below median
Operating margin (12 months)−50.4% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY)4.0% · Below median
Dividend yield (12 months)0.4% · Bottom 25%
Balance sheet
Debt / equity0.02× · Below median
Valuation Multiplesvs Medical Devices median · lower = cheaper
P/E (12 months)235.0× · Priciest 25%
P/B2.83× · Pricier than median
P/S (12 months)4.68× · Pricier than median
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 12
FUTURE (revenue growth)20· sector 32
PAST (return on equity)0· sector 17
HEALTH (low debt)99· sector 98
DIVIDEND (yield)9· sector 37
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Shanghai Aohua Photoelectricity Endoscope Co. Ltd. A Fair Value". https://www.fairvalue-calculator.com/stock/688212
Frequently asked questions
Is Shanghai Aohua Photoelectricity Endoscope Co. Ltd. A (688212) overvalued or undervalued?
As of Oct 26, 2026, our model estimates a fair value of ¥10.08 versus a price of ¥27.58, about −63% upside (overvalued).
What is the fair value of 688212?
Our model-based fair value for Shanghai Aohua Photoelectricity Endoscope Co. Ltd. A is ¥10.08 (as of Oct 26, 2026), built from audited fundamentals. The current price: ¥27.58.
What is the quality score of 688212?
Shanghai Aohua Photoelectricity Endoscope Co. Ltd. A has a Quality Score of 43/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Shanghai Aohua Photoelectricity Endoscope Co. Ltd. A (688212)?
Our model-based price target is the fair value of ¥10.08 (as of Oct 26, 2026) from 16 valuation models. Cautious scenario ¥9.27, optimistic scenario ¥10.08. It is a calculation from audited fundamentals, not an analyst target.
What is the Shanghai Aohua Photoelectricity Endoscope Co. Ltd. A stock forecast for 2026?
Our models put fair value at ¥10.08, about −63% upside versus a price of ¥27.58 (overvalued). Cautious scenario ¥9.27, optimistic scenario ¥10.08. The calculation is refreshed regularly with new filings.
What is the revenue of Shanghai Aohua Photoelectricity Endoscope Co. Ltd. A (688212)?
Shanghai Aohua Photoelectricity Endoscope Co. Ltd. A reported trailing-twelve-month revenue of about 793M CNY (latest available figure, as of Oct 26, 2026).
Does Shanghai Aohua Photoelectricity Endoscope Co. Ltd. A pay a dividend?
Shanghai Aohua Photoelectricity Endoscope Co. Ltd. A currently shows a dividend yield of 0.44% relative to its recent price (as of Oct 26, 2026).
What is the intrinsic value of Shanghai Aohua Photoelectricity Endoscope Co. Ltd. A (688212)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Shanghai Aohua Photoelectricity Endoscope Co. Ltd. A it is ¥10.08 per share (as of Oct 26, 2026), against a price of ¥27.58. It is the blended result of 16 valuation models (cash flow, earnings, asset, dividend).
Is Shanghai Aohua Photoelectricity Endoscope Co. Ltd. A stock overvalued or undervalued in 2026?
As of Oct 26, 2026, 688212 trades above its calculated fair value: price ¥27.58, fair value ¥10.08, a gap of about −63% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 688212?
No. The price is what the market pays today (¥27.58); the fair value is what the company's own numbers justify (¥10.08). For Shanghai Aohua Photoelectricity Endoscope Co. Ltd. A the two are ¥17.50 per share apart. That gap is exactly why we show both numbers side by side.
How much is Shanghai Aohua Photoelectricity Endoscope Co. Ltd. A worth?
The market values Shanghai Aohua Photoelectricity Endoscope Co. Ltd. A at about 3.7B CNY (market capitalisation, as of Oct 26, 2026). Per share that is ¥27.58; our models calculate a fair value of ¥10.08 per share.
What do the bullish and bearish scenarios say about 688212?
Our models span a range for Shanghai Aohua Photoelectricity Endoscope Co. Ltd. A: cautious scenario ¥9.27, base ¥10.08, optimistic ¥10.08 per share (as of Oct 26, 2026, price ¥27.58). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of 688212?
Shanghai Aohua Photoelectricity Endoscope Co. Ltd. A trades at a price-to-earnings ratio of 235.0 (as of Oct 26, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of ¥10.08 is built from several models across several years. Other multiples: P/B 2.8, P/S 4.7.
How solid is the balance sheet of Shanghai Aohua Photoelectricity Endoscope Co. Ltd. A (688212)?
Balance-sheet figures for Shanghai Aohua Photoelectricity Endoscope Co. Ltd. A (as of Oct 26, 2026): return on equity −2.6%, debt of 0.02 per unit of equity. They feed the Quality Score of 43/100, which measures business quality independently of the share price.
How far is 688212 from its 52-week high?
Shanghai Aohua Photoelectricity Endoscope Co. Ltd. A trades at ¥27.58, about 46% below its 52-week high of ¥51.41 and 12% above the low of ¥24.71 (as of Oct 27, 2026). Distance from the high says nothing about value: that is what the fair value of ¥10.08 is for.
Which stocks are comparable to Shanghai Aohua Photoelectricity Endoscope Co. Ltd. A?
From the same area (Healthcare) we also value Abbott Laboratories,, Medtronic plc, Stryker Corporation, Boston Scientific Corporation, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Shanghai Aohua Photoelectricity Endoscope Co. Ltd. A stock attractive at the current price?
The data as of Oct 26, 2026: price ¥27.58, calculated fair value ¥10.08 (−63%), Quality Score 43/100, from 16 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 688212 calculated?
We run Shanghai Aohua Photoelectricity Endoscope Co. Ltd. A through 16 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of ¥10.08, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.2 % above its aggregate fair value. Shanghai Aohua Photoelectricity Endoscope Co. Ltd. A itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Shanghai Aohua Photoelectricity Endoscope Co. Ltd. A (688212)?
The closing price on Oct 27, 2026 was ¥27.58. Our model-based fair value is ¥10.08, about −63% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Shanghai Aohua Photoelectricity Endoscope Co. Ltd. A right now?
The price sits above even our optimistic bull case (¥10.08). The favourable scenario is already priced in. Weak quality (43/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. The models converge in a tight band (¥9.27 to ¥10.08), unusually little disagreement for a valuation.
Key figures of Shanghai Aohua Photoelectricity Endoscope Co. Ltd. A
How large is the market capitalisation of Shanghai Aohua Photoelectricity Endoscope Co. Ltd. A (688212)?
The market capitalisation of Shanghai Aohua Photoelectricity Endoscope Co. Ltd. A is 3.7B CNY (≈ $558M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Shanghai Aohua Photoelectricity Endoscope Co. Ltd. A (688212)?
The price-to-sales ratio of Shanghai Aohua Photoelectricity Endoscope Co. Ltd. A is 3.48 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Shanghai Aohua Photoelectricity Endoscope Co. Ltd. A (688212)?
Earnings per share at Shanghai Aohua Photoelectricity Endoscope Co. Ltd. A are ¥−0.2500 (price ÷ EPS = P/E 235.0). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Shanghai Aohua Photoelectricity Endoscope Co. Ltd. A (688212)?
The dividend yield of Shanghai Aohua Photoelectricity Endoscope Co. Ltd. A is 0.4%. Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Shanghai Aohua Photoelectricity Endoscope Co. Ltd. A (688212)?
The net margin of Shanghai Aohua Photoelectricity Endoscope Co. Ltd. A is −4.2% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Shanghai Aohua Photoelectricity Endoscope Co. Ltd. A (688212)?
The return on equity (ROE) of Shanghai Aohua Photoelectricity Endoscope Co. Ltd. A is −2.6% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Shanghai Aohua Photoelectricity Endoscope Co. Ltd. A (688212)?
On an EBIT basis the return on assets of Shanghai Aohua Photoelectricity Endoscope Co. Ltd. A is 2.7% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Shanghai Aohua Photoelectricity Endoscope Co. Ltd. A (688212)?
The operating margin of Shanghai Aohua Photoelectricity Endoscope Co. Ltd. A is −50.4% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Shanghai Aohua Photoelectricity Endoscope Co. Ltd. A (688212)?
Revenue at Shanghai Aohua Photoelectricity Endoscope Co. Ltd. A is growing +4.0% versus a year earlier (3y avg +20.2%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Shanghai Aohua Photoelectricity Endoscope Co. Ltd. A (688212)?
Earnings per share at Shanghai Aohua Photoelectricity Endoscope Co. Ltd. A are growing +420% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Shanghai Aohua Photoelectricity Endoscope Co. Ltd. A (688212) generate?
The free cash flow of Shanghai Aohua Photoelectricity Endoscope Co. Ltd. A is −151M CNY (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
Free · no account needed
Watch Shanghai Aohua Photoelectricity Endoscope Co. Ltd. A in the live analysis
One click puts Shanghai Aohua Photoelectricity Endoscope Co. Ltd. A on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 28,000+ stock screener.
Thin data
Oct 26, 2026